Macrophage Therapeutics has developed a proprietary targeted steroid (MT-2000 class) designed to specifically treat the disease-causing cells quarterbacking the body’s inflammatory response (Macrophages). MT-2000 is a class of agents that are designed to precisely convert pro-inflammatory M1 Macrophages to anti-inflammatory M2 macrophages. MT’s receptor-based approach eliminates the off-target toxicity associated with the use of typical steroid approaches.
View This Therapeutic Areas of FocusIn cancer, Macrophage Therapeutics has developed a targeted apoptotic agent (MT-1000 class) that exquisitely targets and kills Tumor Associated Macrophages (TAMs). These TAMs are recruited by most tumors to create a pro-tumor microenvironment. MT has demonstrated that this approach effectively eliminates TAMs and stimulates the bodies endogenous immune system to attack the tumor. MT-1000 class will be used in combination with other anti-tumor approaches including immunotherapies, chemotherapeutic agents, and radiation.
View This Therapeutic Areas of Focus